المؤلف: فريق البحث والتطوير، نكهات CUIGUAI
نُشر بواسطة:شركة قوانغدونغ الفريدة للنكهات المحدودة
آخر تحديث: أغسطس 31، عام ٢٠٢٦
واتساب وتيليجرام: +86 189 2926 7983
البريد الإلكتروني：info@cuiguai.com
Prop 65 Decision Workflow
Image caption and alt text: California Proposition 65 exposure assessment workflow for e-liquids.
موارد Cuiguai ذات الصلة: Vape Flavor Ingredient Transparency · Vape Flavor Safety Checklist: Beyond GRAS Flavor Rules · Cool Flavor concentrate · Mango Flavor concentrate
No. Pulegone and beta-myrcene are currently listed by California as chemicals known to cause cancer, but Proposition 65 is an exposure-warning law, not a blanket ingredient ban. A warning decision depends on reasonably anticipated exposure, exemptions and defensible risk assessment. Detectable concentration is not by itself the legal trigger, and natural source is not automatically exempt.
As of this review, neither chemical appears in OEHHA’s regulatory table of established NSRLs and MADLs. Do not invent an “OEHHA threshold” or make a simple pass/fail comparison. A business seeking a no-warning position needs a scientifically valid exposure assessment under the regulations, normally developed with qualified toxicology and California legal review, or it should use a compliant warning.
The Safe Drinking Water and Toxic Enforcement Act of 1986 requires businesses to provide a clear and reasonable warning before knowingly and intentionally causing a significant exposure to a listed chemical, unless an exemption applies. Businesses with fewer than 10 employees are generally exempt, although larger customers may still require disclosure and testing from small suppliers. OEHHA administers the list and warning regulations; public and private enforcement makes documentation important.
For carcinogens, a regulatory NSRL represents daily exposure associated with no more than one excess cancer case per 100,000 people exposed over a 70-year lifetime under Proposition 65 methodology. For reproductive toxicants, a MADL derives from the no-observed-effect level divided by 1,000. OEHHA has established safe-harbor levels for many—but not all—chemicals. Absence of a number does not make zero exposure the law; it means the business cannot rely on a ready-made safe harbor and must support an alternative scientifically valid level or warn.
Concentrate concentration is only one input. Finished-liquid dilution, pod format, device power, aerosol transfer, puffing and daily consumption determine inhalation exposure. Volatile terpenes may transfer efficiently, while heating can deplete a parent or generate products. A concentrate COA cannot substitute for finished-product assessment unless the customer justifies a conservative, validated calculation.
A B2B supplier should disclose concentration, method, quantitation limit, uncertainty, lot and matrix. The finished-product business combines those data with recipe and device evidence. Contracts should state who controls warnings, artwork, online warnings and retailer notices.
Pulegone and beta-myrcene are relevant, but not the only possible listed chemicals in an e-cigarette. Nicotine is listed for developmental toxicity, and device or aerosol studies may identify metals or carbonyls. OEHHA’s e-cigarette fact sheet highlights nicotine and chemicals associated with devices or aerosol. Begin with the complete current list and evaluate the marketed product rather than only two terpenes.
OEHHA states that pulegone is currently listed as causing cancer, effective April 18, 2014 under the Labor Code mechanism. Those are facts a file should cite. The page does not establish that every peppermint product needs a warning and does not supply a universal e-liquid concentration limit. The next step is exposure assessment.
Pulegone is a naturally occurring monoterpene ketone associated with pennyroyal and mint oils. Concentration varies with species, cultivar, geography, harvest, storage and distillation. Published ranges are unsuitable as release specifications. Require exact botanical identity, supplier specification and lot-specific chromatography.
Pennyroyal oil presents an especially strong concern and should not be routine. Identify Latin name, plant part, origin, extraction, adulteration controls and compositional standard. A change in origin or distillation should trigger requalification.
Risk management may include controlled low-pulegone mint materials, reducing natural oil, reconstructing aroma with identified compounds, or avoiding the ingredient. Isolated menthol may remove the pulegone contribution but creates a different profile and still needs purity, impurity, toxicology and market review. Cooling agents should not be called Prop 65 clean without screening the whole product.
Concentration management needs a documented equation. Multiply measured concentrate level by dosage, then apply measured or justified aerosol transfer and reasonably anticipated use. Include units and uncertainty. Conservative assumptions must be identified as assumptions; device-specific conclusions must be limited to tested or bracketed products.
Pulegone and Beta-Myrcene Sources
Image caption and alt text: Pulegone and beta-myrcene source map for mint, hop and botanical flavors.
OEHHA states beta-myrcene is currently listed as causing cancer, with a listing date of March 24, 2015 and basis of Authoritative Bodies—National Toxicology Program. A related notice uses March 27 in its title; quote the chemical database field precisely. Listing is an exposure-screening trigger, not a ban on every natural source.
Beta-myrcene occurs in hop oils, cannabis- or hemp-derived terpene blends, lemongrass and some citrus or tropical-fruit materials. Abundance varies by variety and processing. A mango flavor does not prove natural mango or beta-myrcene is present; many profiles use esters, lactones and sulfur compounds. Conversely, “natural flavor” can hide myrcene-bearing oils. Full disclosure under confidentiality is essential.
For hop or hemp profiles, do not assume carbon-dioxide extraction always lowers myrcene. Conditions can enrich or deplete volatiles. Only lot data support a conclusion. Establish storage controls because beta-myrcene oxidizes and composition shifts with air, light and heat.
Synthetic reconstruction can reduce beta-myrcene while retaining parts of a fruit, hop or botanical impression. Replacements need sensory, impurity, inhalation and thermal review. Removing one listed chemical does not make a product safe, compliant or warning-free. Re-run full-list screening after reformulation and issue new specifications.
GC-MS and Aerosol Assessment
Image caption and alt text: Laboratory GC-MS and aerosol collection for pulegone and beta-myrcene.
GC-MS is logical for volatile terpenes. A compliance-quality method uses traceable standards, multi-level calibration, internal standard, blanks, matrix spikes, duplicates and quality controls. Document selectivity, linearity, recovery, precision, carryover, stability, detection limit, quantitation limit and uncertainty in the relevant PG/VG/nicotine/flavor matrix.
Selected-ion monitoring may improve sensitivity; full-scan data supports identity and broader screening. Define retention time and qualifier-ion ratios. Validate containers, headspace, preparation time and storage because oxidation and adsorption matter. Report non-detects as below a stated reporting limit, not zero.
Test representative materials and concentrates, then set frequency from variability and controls. Botanical lots may require every-lot testing; a controlled synthetic material may justify reduced frequency after qualification. Composite samples can hide outliers. Retain sealed material for investigations.
When customers use multiple dosages, report mass-based results with density assumptions. Do not give one safe use percentage unless linked to a defined product, exposure model, device and risk assessment. Distinguish analytical specifications from legal conclusions.
Aerosol testing should reflect marketed device and anticipated use. Record model, coil, power, airflow, puff volume, duration, interval, puff number, conditioning, liquid consumed and collection efficiency. CORESTA methods offer a reproducible starting point but must be validated for the analytes and product. Include blanks and mass balance where feasible.
Transfer efficiency is the proportion in consumed liquid recovered in aerosol. It varies with volatility, temperature, formulation and collection. Use measured data; if 100% transfer is assumed for screening, state that it is an assumption. Evaluate transformation products separately.
Start with measured concentration and uncertainty. Apply dilution, daily consumption or puff-based yield, and justified transfer or retention. Keep units explicit so milligrams per kilogram, micrograms per milliliter and micrograms per day are not confused. Use a reasonably anticipated rate under regulations rather than an unrealistically low average.
Run sensitivity analyses for high use, device variation, batch maximum, aging and uncertainty. State populations and routes. If dermal or oral exposure from filling or leakage is plausible, assess it. Legal review should confirm averaging and whether an alternative risk level meets the standard.
Where OEHHA has not promulgated an NSRL, a business can seek to demonstrate no significant risk using scientifically valid principles consistent with Proposition 65. This is toxicological risk assessment, not marketing math. It may require dose-response modeling, route considerations, pharmacokinetics and study-quality evaluation. A settlement level from another company is not automatically a safe harbor.
Preserve expert report, literature search, data files, workbook, version control and legal approval. Reassess when formula, supplier, device, use, law or science changes. If the record cannot support the conclusion, warn or reformulate.
A non-detect means below a validated reporting limit, not chemical-free. A regulatory safe harbor applies to exposure, not ingredient concentration. Where no safe harbor exists, obtain alternative assessment, warn or reformulate. Formula and device changes require impact review. If warning is selected, use current wording and delivery rather than an outdated generic short form.
Title 27 provides safe-harbor methods and content. A consumer-product cancer warning generally uses the symbol, signal word, at least one cancer chemical, and the warnings website. Exact wording depends on exposure and section. Verify the current regulation and exposure type at artwork approval rather than copying an old label.
OEHHA adopted short-form amendments in 2024. They became effective January 1, 2025 and include a three-year transition structure. The revised short form identifies at least one chemical, unlike the older generic Cancer format. Review manufacturing dates, inventory, online/catalog warnings, retailer communication and contracts before relying on transition.
Warning language is legal content, so this guide gives no universal copy block. Use current Title 27 wording, documented approval and pre-purchase online delivery where required. Do not bury the warning after checkout.
Suppliers should communicate listed chemicals and data. The finished-product manufacturer controls dilution, device and labeling; retailers may control online display. Agreements should identify authorized warning, chemical, placement, language, transition and change process. Keep proof downstream parties received updates.
Cuiguai Prop 65 Documentation
Image caption and alt text: E-liquid flavor documentation review for California Proposition 65.
Set analyte limits linked to finished-product risk management, not historical supplier data. Account for maximum dosage, uncertainty, device assumptions and safety margin. For different applications, provide analyte results and application-specific guidance rather than one global claim.
Use formal deviation and change control. An above-limit result triggers quarantine, investigation and customer impact review. A new source, process or carrier triggers requalification even under the same trade name. Trend data to identify drift.
No. They are listed carcinogens. Proposition 65 generally requires warnings for qualifying exposures, not bans.
Pulegone: April 18, 2014, Labor Code. Beta-myrcene: March 24, 2015, Authoritative Bodies—NTP.
Neither appears in the current regulatory table. Do not invent numbers.
No. Detection starts exposure assessment; it is not the final conclusion.
Rules are fact dependent and should not be assumed for e-liquid or processed flavor ingredients. Obtain advice.
Usually not. Account for dilution, device, aerosol and use, and screen other listed chemicals.
No universal method is prescribed. GC-MS is suitable but must be validated.
They can provide data, but finished-product conclusions depend on exposure and use.
The 2024 amendments effective January 1, 2025 require identifying at least one chemical, with transition provisions.
No. Nicotine and other product or aerosol chemicals may be listed.
Base frequency on variability, supplier controls, capability and change risk.
Cuiguai can discuss samples, composition, specifications and targeted data. California sellers control final assessment and warning.
The reliable workflow is: screen the current list, quantify chemicals with a validated method, test or conservatively model the marketed product and device, estimate reasonably anticipated exposure, obtain qualified review, and document an exemption, warn correctly or reformulate. These analytes matter because natural oils can introduce them, not because every detectable amount violates law.
The key correction is that OEHHA has not supplied an established regulatory NSRL for either in its current table. Suppliers should report measured facts and conditions, not convert concentration into an unsupported legal guarantee. Transparent scope, units, uncertainty and change control make data useful.
Cuiguai can discuss flavor profiles, natural-oil alternatives, samples and available analytical documentation. Provide concentrate dose, base, nicotine status, device, California sales plan and analytes. Cuiguai does not replace finished-product counsel, toxicology, device testing or warning decisions.
Technical consultation and documentation requests:
الموقع الإلكتروني: https://www.cuiguai.com
البريد الإلكتروني: info@cuiguai.com
هاتف: +86 0769 88380789
واتساب وتليغرام: +86 189 2926 7983
[1] OEHHA. Pulegone. https://oehha.ca.gov/proposition-65/chemicals/pulegone
[2] OEHHA. Beta-Myrcene. https://oehha.ca.gov/proposition-65/chemicals/beta-myrcene
[3] OEHHA. NSRLs and MADLs. https://oehha.ca.gov/proposition-65/general-info/proposition-65-no-significant-risk-levels-nsrls-and-maximum-allowable-dose-levels-madls
[4] OEHHA. Proposition 65 List. https://oehha.ca.gov/proposition-65/proposition-65-list
[5] P65Warnings. Electronic Cigarettes. https://www.p65warnings.ca.gov/fact-sheets/electronic-cigarettes-e-cigarettes
[6] California Code of Regulations, Title 27, Article 6. https://govt.westlaw.com/calregs/
[7] OEHHA. Proposition 65 regulatory notices and 2024 short-form amendments. https://oehha.ca.gov/proposition-65
[8] California Health and Safety Code §§25249.5–25249.14. https://leginfo.legislature.ca.gov/
[9] National Toxicology Program. β-Myrcene studies. https://ntp.niehs.nih.gov/
[10] CORESTA. Recommended Methods. https://www.coresta.org/recommended-methods
يشمل نطاق الأعمال المشاريع المرخصة: إنتاج المواد المضافة للأغذية. المشاريع العامة: بيع المواد المضافة للأغذية؛ تصنيع المنتجات الكيميائية اليومية؛ بيع المنتجات الكيميائية اليومية؛ خدمات فنية، تطوير التكنولوجيا، استشارات فنية، تبادل التكنولوجيا، نقل التكنولوجيا، وترويج التكنولوجيا؛ أبحاث وتطوير الأعلاف البيولوجية؛ أبحاث وتطوير مستحضرات الإنزيم الصناعية؛ بيع الجملة لمستحضرات التجميل؛ وكالة تجارية محلية؛ بيع المنتجات الصحية والإمدادات الطبية ذات الاستخدام الواحد؛ بيع الأدوات المنزلية والمواد الصحية والسلع اليومية؛ بيع الضروريات اليومية؛ بيع الأغذية (فقط بيع الأطعمة المعبأة مسبقًا).
Copyright ©شركة قوانغدونغ الفريدة للنكهات المحدودةAll Rights Reserved. Privacy Policy Return and Exchange Policy
